Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.59 |
| ▸ | TP53 | P04637 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | SMPD1 | P17405 | 6/20 | 0.45 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.41 |
| ▸ | BLM | P54132 | 2/20 | 0.40 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fantofarone SCHEMBL29802340 | 1.00 | CYP3A4 (0.59) | CYP3A4KDM4ETP53MAPTTSHR | |
| Fantofarone SCHEMBL9599714 | 0.99 | CYP3A4 (0.59) | CYP3A4KDM4ETP53MAPTTSHR | |
| SCHEMBL9598076 | 0.98 | CYP3A4 (0.57) | CYP3A4KDM4ETP53MAPTTSHR | |
| SCHEMBL9156142 | 0.93 | KDM4E (0.51) | CYP3A4KDM4ETP53MAPTTSHR | |
| SCHEMBL9157509 | 0.92 | CYP3A4 (0.50) | CYP3A4KDM4ETP53MAPTTSHR | |
| Hydrochloric Acid SCHEMBL9655914 | 0.92 | CYP3A4 (0.49) | CYP3A4KDM4ETP53MAPTTSHR | |
| SCHEMBL9598112 | 0.90 | KDM4E (0.56) | CYP3A4KDM4ETP53MAPTTSHR | |
| SCHEMBL9656156 | 0.90 | KDM4E (0.46) | CYP3A4KDM4ETP53MAPTTSHR | |
| SCHEMBL9215666 | 0.89 | KDM4E (0.48) | CYP3A4KDM4ETP53MAPTTSHR | |
| SCHEMBL9155096 | 0.88 | CYP3A4 (0.57) | CYP3A4KDM4ETP53MAPTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1344 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3498297-B1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF AUTISM | STALICLA S A (CH) | 2023-06-21 | — | — | EP | claimed |
| US-20210154177-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF AUTISM | Stalicla S.A. (CH) | 2021-05-27 | — | — | US | claimed |
| US-20210145803-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF AUTISM | Stalicla S.A. (CH) | 2021-05-20 | — | — | US | claimed |
| EP-3498297-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF AUTISM | Stalicla S.A. (CH) | 2019-06-19 | — | — | EP | claimed |
| CN-109821019-A | Pharmaceutical composition for treating autism | 斯塔利克拉股份有限公司 | 2019-05-31 | — | — | CN | claimed |
| US-20190134011-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF AUTISM | Stalicla S.A. (CH) | 2019-05-09 | — | — | US | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-20140142124-A1 | Compositions for Topical Application Having Androgenic Actions | AVENTIS PHARMA SA (DE) | 2014-05-22 | — | — | US | claimed |
| US-8268352-B2 | Modified release composition for highly soluble drugs | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-18 | — | — | US | claimed |
| US-8263125-B2 | Dosage form for high dose-high solubility active ingredients that provides for immediate release and modified release of the active ingredients | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-11 | — | — | US | claimed |
| WO-1999067231-A1 | NITRATE SALTS OF ANTIHYPERTENSIVE MEDICINES | NICOX S.A. (FR) | 1999-12-29 | — | — | WO | claimed |
| CN-1210460-A | Preparations stimulating nail growth | HOECHST AG (DE) | 1999-03-10 | — | — | CN | claimed |
| EP-0858325-A1 | STABLE FREEZE-DRIED PHARMACEUTICAL FORMULATION | SANOFI (FR) | 1998-08-19 | — | — | EP | claimed |
| WO-1997017064-A1 | STABLE FREEZE-DRIED PHARMACEUTICAL FORMULATION | SANOFI (FR) | 1997-05-15 | — | — | WO | claimed |
| WO-1996010406-A1 | PHARMACEUTICAL COMPOSITION OF FANTOFARONE FOR ORAL ADMINISTRATION | SANOFI (FR) | 1996-04-11 | — | — | WO | claimed |
| EP-0639986-A1 | TOPICAL OPHTHALMIC COMPOSITIONS COMPRISING A COMBINATION OF CALCIUM ANTAGONISTS WITH KNOWN ANTIGLAUCOMA AGENTS | ALCON LABORATORIES, INC. (US) | 1995-03-01 | — | — | EP | claimed |
| WO-1993023082-A1 | TOPICAL OPHTHALMIC COMPOSITIONS COMPRISING A COMBINATION OF CALCIUM ANTAGONISTS WITH KNOWN ANTIGLAUCOMA AGENTS | ALCON LABORATORIES, INC. (US) | 1993-11-25 | — | — | WO | claimed |
| US-5017579-A | Use of aminoalkoxyphenyl derivatives for reducing and/or controlling excessive intraocular pressure | SANOFI (FR) | 1991-05-21 | — | — | US | claimed |
| EP-0235111-B1 | INDOLIZINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM | SANOFI S.A. (FR) | 1991-04-10 | — | — | EP | claimed |
| US-4957925-A | HYPOTENSIVE AGENTS, ANTIARRHYTHMIA AGENTS, TREATMENT OF ANGINA | SANOFI (FR) | 1990-09-18 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140142124-A1 | Compositions for Topical Application Having Androgenic Actions | NR5A1, CYP17A1, CYP19A1 | CYP3A4 2887/4885KDM4E 3855/4885TP53 2342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.